GlassScriptPhysician profile
Krishnaswami Vijayaraghavan
NPI 1376598151
$927,309.97
in general payments reported to CMS, 2019-2025
38 companies · $19K in 2025
The $19K reported for 2025 was more than what 96% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $215K · 2020: $156K · 2021: $172K · 2022: $157K · 2023: $103K · 2024: $106K · 2025: $19K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $100K · Honoraria: $66K · Consulting Fee: $34K · Travel and Lodging: $21K · Food and Beverage: $6,556 · Education: $1.18.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $100,322.00 |
| Honoraria | $65,520.00 |
| Consulting Fee | $34,168.66 |
| Travel and Lodging | $21,119.10 |
| Food and Beverage | $6,555.80 |
| Education | $1.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $231,625.61 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $114,609.40 | 2019-2024 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $102,776.89 | 2019-2025 | Wainua |
| Lilly USA, LLC | $101,713.04 | 2019-2024 | Jardiance, Mounjaro |
| Amarin Pharma, INC. | $78,679.23 | 2019-2024 | |
| Lexicon Pharmaceuticals, INC. | $75,428.27 | 2023-2024 | Inpefa |
| Pfizer INC. | $56,819.32 | 2019-2024 | |
| Kiniksa Pharmaceuticals International, Plc | $31,692.86 | 2024 | Arcalyst |
| Eli Lilly and Company | $30,600.00 | 2020-2022 | |
| Kiniksa Pharmaceuticals, LTD. | $21,788.48 | 2023 | Arcalyst |
| Amgen INC. | $19,669.88 | 2019-2023 | Repatha |
| Scpharmaceuticals INC. | $15,567.12 | 2023-2025 | |
| Esperion Therapeutics, INC. | $13,055.86 | 2021-2023 | Nexletol |
| Novartis Pharmaceuticals Corporation | $8,706.09 | 2019-2023 | |
| Baxter Healthcare | $5,026.53 | 2019-2020 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Krishnaswami Vijayaraghavan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.